A Research on Formulation and Evaluation of Celecoxib Fast Disintegrating Capsule (200mg)

PINKY BISHT

doi:10.36948/ijfmr.2025.v07i04.50606

A Research on Formulation and Evaluation of Celecoxib Fast Disintegrating Capsule (200mg)

Author(s)	Ms. PINKY BISHT
Country	India
Abstract	Fast-disintegrating capsules have gained significant interest due to their potential to enhance patient compliance and drug efficacy. Celecoxib, a non-steroidal anti-inflammatory drug (NSAID), known for its selective inhibition of cyclooxygenase-2 (COX-2), is commonly used for the management of pain and inflammation associated with arthritis and other conditions. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits cyclooxygenase- 2 (COX-2),enzyme involved in the synthesis of prostaglandins. Prostaglandins play a key role in inflammation, pain perception, and fever response. By selectively inhibiting COX-2, celecoxib reduces the production of prostaglandins that promote inflammation and pain, while sparing COX-1 activity to a greater extent. This study aimed to develop and evaluate a fast-disintegrating capsule formulation of Celecoxib to provide rapid onset of action and improved patient convenience. The formulation was optimized using a combination of superdisintegrants and excipients to achieve fast disintegration in oral cavity conditions. Physicochemical characterization including disintegration time,and drug content uniformity were evaluated. In vitro dissolution studies were conducted to assess drug release profiles. The optimized formulation demonstrated rapid disintegration within seconds and showed comparable dissolution profiles to commercially available Celecoxib capsules. Further studies are warranted to evaluate the pharmacokinetic and pharmacodynamic profiles of the fast-disintegrating Celecoxib capsule in clinical settings to validate its potential therapeutic benefits.
Keywords	IID- Inactive Ingredient Database, CMA- Critical Material Attributes, Quality Target Product Profile, Critical Process Parameters, Percentage Relative Standard Deviation, Particle size distribution, COX)-2 inhibitors (coxibs), NSAIDs, Celebrex, Super disintegrant, Drug interaction .
Field	Medical / Pharmacy
Published In	Volume 7, Issue 4, July-August 2025
Published On	2025-07-09
DOI	https://doi.org/10.36948/ijfmr.2025.v07i04.50606
Short DOI	https://doi.org/g9s9md

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 4 Cover Page Vol 7 Isu 3 Cover Page Vol 7 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

A Research on Formulation and Evaluation of Celecoxib Fast Disintegrating Capsule (200mg)

Share this